Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
To determine whether an accelerated course of radiotherapy delivered to the lumpectomy cavity plus margin using IORT as a single dose, intracavitary brachytherapy with the MammoSite device over 5 days, partial breast 3-D CRT in 5 days, or stereotactic APBI over 4 days is a feasible and safe alternative to a six and a half week course of whole breast radiotherapy. The study will measure both short and long-term complications of radiation treatment, short and long-term breast cosmesis, local rates of in-breast cancer recurrence, regional recurrences, distant metastases, and overall survival.
Condition | Intervention |
---|---|
Breast Cancer Carcinoma, Ductal |
Radiation: Intra-Operative Radiotherapy (IORT) Procedure: Lumpectomy Radiation: Whole Breast Radiotherapy Radiation: Intracavitary Brachytherapy Radiation: Accelerated External Beam 3-D Conformal Radiotherapy Radiation: Stereotactic APBI |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer |
- Determination of whether accelerated radiotherapy or stereotactic APBI is a feasible and safe alternative to whole breast radiotherapy.
Estimated Enrollment: | 400 |
Study Start Date: | September 2002 |
Estimated Study Completion Date: | December 2015 |
Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Accelerated Partial Breast Irradiation |
Radiation: Intra-Operative Radiotherapy (IORT)
single dose in the operating room after lumpectomy
Procedure: Lumpectomy
Radiation: Intracavitary Brachytherapy
5 day treatment
Other Name: MammoSite
Radiation: Accelerated External Beam 3-D Conformal Radiotherapy
5 day treatment
Radiation: Stereotactic APBI
4 day treatment
|
Active Comparator: Standard Therapy |
Procedure: Lumpectomy
Radiation: Whole Breast Radiotherapy
six and a half week treatment
|
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:1. Women >= 40 with invasive ductal carcinoma or ductal carcinoma in situ
2. Patient chooses lumpectomy rather than mastectomy as treatment for breast cancer
3. Tumor < 2.5 cm in size, 2 mm margin of normal breast tissue between cancer and edge of specimen.
Exclusion Criteria:1. Men
2. Prior malignancy, breast or other if metastatic or with anticipated survival of < 5 years
3. Pregnant women
4. Immunocompromised
5. Poorly controlled insulin dependent diabetes
6. Contraindication to radiotherapy, e.g. connective tissue disorder such as scleroderma
7. Breast cancer that involves skin or chest wall
8. Multifocal or Multicentric breast cancer
9. Invasive lobular carcinoma
10. Diffuse microcalcifications on mammography
11. Invasive carcinoma with extensive intraductal component (EIC)
12. Greater than 12 weeks since definitive surgical excision or completion of chemotherapy
13. Involved lymph nodes detected by frozen section or touch preparation at time of lumpectomy
14. Patients with 1 to 3 positive lymph nodes determined postoperatively (does not include patients with micro-metastases)
15. Subglandular or submuscular breast implants (does not include patients having implants placed AFTER intra-operative radiotherapy)
United States, California | |
Stanford University School of Medicine | |
Stanford, California, United States, 94305 |
Principal Investigator: | Frederick M. Dirbas | Stanford University |
No publications provided
Responsible Party: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00185744 History of Changes |
Other Study ID Numbers: | BRSNSTU0003, 78466, BRSNSTU0003, 13807 |
Study First Received: | September 12, 2005 |
Last Updated: | May 14, 2012 |
Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Additional relevant MeSH terms:
Breast Neoplasms Carcinoma Carcinoma, Ductal Neoplasms by Site Neoplasms Breast Diseases |
Skin Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Adenocarcinoma Neoplasms, Ductal, Lobular, and Medullary |
ClinicalTrials.gov processed this record on March 06, 2013